Exact Sciences stock is trading -17.39% below its average target price of $63.14 after marking a 5.9% during today's afternoon session. Analysts are giving the Mid-Cap Medical Specialities company an average rating of buy and target prices ranging from $50.0 to $80.0 per share.
Exact Sciences has an average level of shares sold short, at 5.7% of its total share float. The stock's short ratio (also called days to cover) is 2.64. Only 0.91% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders.
Institutional investors own 95.6% of Exact Sciences's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Exact Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | FMR, LLC | 14% | 26,892,316 | $1,402,703,198 |
| 2025-06-30 | Capital World Investors | 10% | 18,200,022 | $949,313,144 |
| 2025-06-30 | Vanguard Group Inc | 9% | 17,907,459 | $934,053,058 |
| 2025-06-30 | Wellington Management Group, LLP | 6% | 12,003,790 | $626,117,684 |
| 2025-06-30 | Blackrock Inc. | 6% | 10,532,600 | $549,380,414 |
| 2025-06-30 | State Street Corporation | 3% | 5,379,027 | $280,570,047 |
| 2025-06-30 | Price (T.Rowe) Associates Inc | 2% | 3,703,265 | $193,162,301 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 3,237,040 | $168,844,005 |
| 2025-06-30 | Massachusetts Financial Services Co. | 2% | 2,969,613 | $154,895,013 |
| 2025-06-30 | Mackenzie Financial Corporation | 2% | 2,855,801 | $148,958,579 |
